Request Demo

Last update 23 Jan 2026

Mometasone Furoate

Last update 23 Jan 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ASCEND mometasone furoate-coated sinus balloon, Bioabsorbable mometasone-eluting sinus implants - Intersect ENT, Controlled-release-mometasone-furoate

+ [49]

Target

Action

agonists

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesOtorhinolaryngologic Diseases+ [3]

Active Indication

Chronic rhinosinusitis with nasal polypsRhinitis, Allergic, PerennialRhinitis, Allergic, Seasonal+ [17]

Inactive Indication

Acute sinusitisairway diseaseCongestion of nasal mucosa+ [11]

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization

Sandoz Pty Ltd.

Lyra Therapeutics, Inc.

Merck & Co., Inc.

+ [8]

Inactive Organization

Novartis Pharmaceuticals Corp.

Dignity Sciences Ltd.

PH & T SpA

+ [8]

License Organization

Beijing Xinglin Pharmaceutical Co. Ltd.LianBio

Beijing Jiu He Pharmaceutical Ltd.

+ [5]

Drug Highest PhaseApproved

First Approval Date

United States (30 Apr 1987),

InflammationPruritus

RegulationOrphan Drug (United States)

Structure/Sequence

Molecular FormulaC27H30Cl2O6

InChIKeyWOFMFGQZHJDGCX-ZULDAHANSA-N

CAS Registry83919-23-7

310

Clinical Trials associated with Mometasone Furoate

ChiCTR2600116535

/ Not yet recruitingNot ApplicableIIT

A single-blind, single-center clinical study evaluating the efficacy of layered selective laser combined with mometasone ointment in the treatment of melasma

Start Date01 Mar 2026

Sponsor / Collaborator

The Third Xiangya Hospital of Central South University

ChiCTR2500112481

/ Not yet recruitingPhase 4IIT

A prospective, randomized, controlled study comparing the efficacy of intranasal corticosteroids (INCS) combined with intranasal antihistamines (INAH) and INCS combined with oral antihistamines (OAH) in the treatment of moderate to severe allergic rhinitis symptoms

Start Date01 Nov 2025

Sponsor / Collaborator

China-Japan Union Hospital of Jilin University

ChiCTR2500109003

/ Not yet recruitingPhase 4IIT

Efficacy Evaluation of Omalizumab Injection in Patients with Uncontrolled Perennial Moderate-to-Severe Allergic Rhinitis: A Multicenter, Randomized, Open-Label, Investigator-Initiated Study （OPERA Study）

Start Date01 Sep 2025

Sponsor / Collaborator

Yantai Yuhuangding Hospital

100 Clinical Results associated with Mometasone Furoate

100 Translational Medicine associated with Mometasone Furoate

100 Patents (Medical) associated with Mometasone Furoate

1,694

Literatures (Medical) associated with Mometasone Furoate

01 Feb 2026·VETERINARY JOURNAL

A novel approach to treating canine otitis externa with medical ozone: A comparative clinical, cytological and microbiological research

Article

Author: Beker, Selda ; Gül Satar, Nihal Y ; Ünlü, Elif ; Demirbilek, Serpil Kâhya

Otitis externa (OE), an inflammation of the external ear canal, is common in both humans and companion animals and often requires prolonged antimicrobial therapy. Ozone has gained attention for its antimicrobial, antiviral, and antioxidant properties in dermatologic disorders, although its optimal dose and route of administration remain unclear. This study aimed to evaluate the efficacy of topical ozone therapy for managing OE compared with conventional antimicrobial treatments. Twenty-seven client-owned dogs with OE were enrolled in an open-label, prospective, controlled clinical trial and assigned to three groups: ozone (Group I), ciprofloxacin drops (Group II), and a veterinary otic solution with florfenicol, terbinafine, and mometasone furoate (Group III). Clinical assessments (OTIS-3, otoscopy, pain, pruritus, cytology) were performed on days 0, 7, 14, and 21, with bacteriological evaluations on days 0 and 21. Based on OTIS-3, treatment success rates were 100 % in Group I, 33.33 % in Group II, and 66.66 % in Group III. Significant improvements in OTIS-3, otoscopy, pain, and pruritus scores were observed in Group I compared to Group II (p < 0.05). Cytological improvement was significant in Groups I (p < 0.001) and III (p = 0.003). Microbiological analysis confirmed the complete absence of bacterial growth in Group I, effectively eliminating Staphylococcus pseudointermedius, Proteus mirabilis, Bacillus spp., Citrobacter braakii, Coagulase-Negative Staphylococci, Escherichia coli, Dermacoccus nishiomiyaensis, and multidrug-resistant Acinetobacter baumannii. These findings highlight the potential of topical ozone therapy as a safe and effective option for the management of otitis externa, with important implications for reducing antimicrobial use and mitigating antimicrobial resistance.

01 Jan 2026·JOURNAL OF ETHNOPHARMACOLOGY

Yu-Ping-Feng nasal drops relieve allergic rhinitis via TRPV1/Ca2+/NFAT pathway

Article

Author: Ren, Qiuyi ; Hu, Yucheng ; Luo, Hongping ; Li, Junjie ; Tian, Li ; Wang, Xiaobo ; Wang, Fu ; Fu, Linyou

ETHNOPHARMACOLOGICAL RELEVANCE:

Allergic rhinitis (AR) is a chronic inflammatory disorder of the nasal mucosa mediated by immunoglobulin E (IgE). Yu-Ping-Feng nasal drops (YPFND), a compound derived from traditional Chinese medicine, is extensively utilized in the management of respiratory ailments, including AR. Nonetheless, the precise biological pathways through which YPFND influences AR are yet to be fully elucidated.

PURPOSE:

We aim to investigate the bioactivity of YPFND against AR and its therapeutic potential molecular mechanism.

METHODS:

We conducted a 14-day randomized controlled trial involving 60 AR patients assigned to control group (10 % YPFND solution, Con group), mometasone furoate group (MFN group), and YPFND group, with nasal symptom outcomes assessed post-treatment. In parallel, an ovalbumin (OVA)- developed AR rat model was established to investigate the effect of YPFND on nasal mucosal inflammation. Nasal tissues and serum were analyzed by ELISA, Western blot, quantitative PCR (qPCR), histology, immunofluorescence and flow cytometry. Chemical constituents of YPFND were identified via LC-MS/MS. Serum proteomics in control and OVA-induced AR rats was analyzed by nano-HPLC-MS/MS with DIA-NN identification and MaxLFQ quantification. Molecular docking and molecular dynamics (MD) simulations were performed to predict the binding affinity of active compounds to the transient receptor potential vanilloid 1 (TRPV1) protein. In vitro, human nasal epithelial cells (HNEpC) were stimulated with interleukin-17 A (IL-17 A) to induce inflammation. The effects of YPFND on TRPV1-mediated Ca²⁺ influx and nuclear factor of activated T cells (NFAT) activation were assessed, and TRPV1 specificity was confirmed using the antagonist SB-366791.

RESULTS:

LC-MS/MS analysis identified 984 compounds, among which molecular docking revealed nine candidates exhibiting strong binding affinity to TRPV1. Subsequently, MD simulations confirmed the stability of the 5-O-methylvisammioside-TRPV1 complex. Quantitative proteomics quantified 9978 proteins and identified 527 significantly altered proteins (259 upregulated, 268 downregulated) between OVA-induced AR and control rats, enriched in pathways including inflammatory mediator regulation of TRP channels. YPFND significantly alleviated clinical and experimental AR symptoms. In HNEpC, IL-17 A stimulated the expression of TRPV1 and facilitated Ca²⁺ influx. YPFND inhibited the IL-17 A-provoked NFAT expression via the TRPV1/Ca²⁺ signaling pathway. In addition, YPFND ameliorated airway inflammation by inhibiting the TRPV1/NFAT pathway in AR rats and down-regulated the expression of retinoic acid receptor-related orphan receptor gamma t (RORγ-t), further regulating the balance between T helper 17 (Th17) cells and regulatory T (Treg) cells.

CONCLUSION:

Our research elucidates a novel IL-17A/TRPV1/Ca²⁺/NFAT signaling cascade as a critical mediator of Th17/Treg disequilibrium in AR. Moreover, it demonstrates that YPFND exerts anti-inflammatory effects by attenuating TRPV1-dependent Ca²⁺ influx and its downstream NFAT activation.

01 Dec 2025·Lancet Respiratory Medicine

Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial

Article

Author: Mullol, Joaquim ; Wagenmann, Martin ; Martin, Antonio ; Springer, Michal ; Angello, James T ; De Corso, Eugenio ; Corbett, Mark ; Deniz, Yamo ; Radwan, Amr ; Viana, Miguel ; Canonica, G Walter ; Gevaert, Philippe ; Michel, Justin ; Hellings, Peter W ; Nash, Scott ; Zaghloul, Sherif ; Horváth, Zsuzsanna ; Heffler, Enrico ; Grzegorzek, Tomasz ; Peters, Anju T ; Zhang, Mei

BACKGROUND:

Chronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly driven by type 2 inflammation. The biologics dupilumab and omalizumab, which target drivers and mediators of type 2 inflammation (interleukin [IL]-4/IL-13 signaling and immunoglobulin E [IgE], respectively), are efficacious in treating CRSwNP but direct comparisons are few. In EVEREST (EValuating trEatment RESponses of dupilumab versus omalizumab), the first head-to-head trial in respiratory biologics, we aimed to compare the efficacy and safety of dupilumab and omalizumab in patients with severe CRSwNP who had mild, moderate, or severe asthma.

METHODS:

EVEREST was an international, randomised, double-blind, phase 4 trial, conducted at 100 hospitals or clinical centres in 17 countries. Sites were selected with otolaryngology, pneumologist, allergist, and immunologist practices; needed to have previously conducted double-blind studies; and were required have nasal endoscopy and electrocardiogram machines. Eligible patients aged 18 years or older with severe uncontrolled CRSwNP (with a nasal polyp score of 5 or more [and ≥2 for each nostril]), symptoms of nasal congestion and loss of smell for at least 8 weeks before screening, and physician-diagnosed asthma. Patients were randomly assigned (1:1) to subcutaneous dupilumab 300 mg every 2 weeks or omalizumab weight-tiered and IgE-tiered dosing every 2 weeks or 4 weeks for 24 weeks, with background mometasone furoate nasal spray. Patients and investigators were masked to the study drugs. Primary endpoints were change from baseline in endoscopic nasal polyp score and University of Pennsylvania Smell Identification Test (UPSIT) at 24 weeks. Efficacy was assessed in the intention-to-treat population and safety was assessed in patients who received at least one dose of study medication. The trial was registered at ClinicalTrials.gov, NCT04998604.

FINDINGS:

Between Sept 27, 2021, and Dec 27, 2024, 819 individuals were screened for study inclusion, 459 were excluded (most common screen failures were: 167 did not meet nasal polyp score ≥5 or did not have ongoing symptoms of nasal congestion and loss of smell, 114 did not meet pre-bronchodilator FEV₁ ≤85% predicted normal, and 99 did not meet eligibility as per omalizumab drug-dosing), and 360 participants were randomly assigned (181 assigned to the dupilumab group and 179 assigned to the omalizumab group). Of the 360 participants, 198 (55%) participants were male, 162 (45%) were female, and the mean age of the total population sample was 52 years (SD 13·1). Improvements were significantly greater with dupilumab than omalizumab for all primary and secondary efficacy endpoints at week 24. Least squares mean differences in change from baseline dupilumab over omalizumab were: nasal polyp score -1·60 (95% CI -1·96 to -1·25; p<0·0001) and UPSIT 8·0 (6·3 to 9·7; p<0·0001). 115 (64%) of 179 participants in the dupilumab group and 116 (67%) of 173 participants in the omalizumab group reported treatment-emergent adverse events, the most common of which were nasopharyngitis, accidental overdose, headache, upper respiratory tract infection, and cough. There were no deaths in the study.

INTERPRETATION:

Dupilumab was superior to omalizumab in patients with severe CRSwNP and coexisting asthma. These findings support the efficacy of dupilumab in patients with type 2 respiratory diseases versus an active biologic comparator, the known safety profiles of dupilumab and omalizumab, and could enable better treatment targeting for patients with CRSwNP and asthma in clinical practice.

FUNDING:

Sanofi and Regeneron Pharmaceuticals.

112

News (Medical) associated with Mometasone Furoate

12 Jan 2026

·firstwordpharma.com

Biopharma bites: Teva, Kinaset pull in funds, Camzyos wins in teens, plus contrasting fortunes for Lynk, Lyra

Teva again turns to Royalty for funding assistIn an effort to speed development of its anti-IL-15 antibody TEV-’408, Teva has sold certain rights to Royalty Pharma for up to $500 million, including an initial $75 million to support a Phase IIb study in vitiligo. Royalty Pharma also has an option to commit a further $425 million to co-fund a Phase III programme."This agreement…enables us to advance our science more efficiently and accelerate our pipeline," said Richard Francis, Teva's CEO. The Israeli drugmaker is increasingly investing in innovative medicines as part of its strategy to transition away from its pure-play generics past into a biopharmaceutical company.Teva said that emerging data from ongoing Phase Ib work provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions, with results set to be shared this year. TEV-'408 is also in Phase IIa development for coeliac disease.If TEV-'408 is approved and launched, Teva will pay a milestone to Royalty Pharma and a royalty on worldwide net sales of the drug. The agreement mirrors one signed between the parties in 2023 focused on a once-monthly subcutaneous version of Eli Lilly's atypical antipsychotic Zyprexa (olanzapine), known as TEV-'749, which was recently submitted to the FDA.Kinaset raises $103M to advance inhaled JAK inhibitorKinaset Therapeutics closed an oversubscribed $103-million series B round to advance frevecitinib (KN-002), a novel inhaled pan-JAK inhibitor for patients with severe asthma inadequately controlled by standard maintenance therapies. The latest fundraise was led by RA Capital Management and Forge Life Science Partners, with contributions from new financers EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, Sixty Degree Capital and existing backers Atlas Venture, 5AM Ventures and Gimv.The biotech noted that the proceeds will fund a Phase II study of frevecitinib, which targets both eosinophilic and non-eosinophilic asthma phenotypes. "Frevecitinib has the potential to benefit all patients with severe asthma, including those with a non-eosinophilic phenotype," said Robert Clarke, chief executive of Kinaset.Kinaset debuted in 2020 backed by a $40-million series A commitment, alongside securing a global exclusive licence from Vectura to develop and commercialise frevecitinib.Lynk secures Phase III win for oral antirheumatic drugLynk Pharmaceuticals on Monday said its oral JAK1 inhibitor zemprocitinib (LNK01001) — commercially partnered with Simcere in Greater China — met the primary and key secondary goals in a Phase III trial involving patients with moderate-to-severe rheumatoid arthritis who have had an inadequate response to biologic disease-modifying drugs.The study enrolled 430 patients, who were randomised to receive zemprocitinib 12 mg or placebo twice daily, with the primary endpoint being ACR20 — a composite measure of disease improvement. At week 24, the ACR20 response rate with zemprocitinib was 79.1%, which was significantly greater than the 39.7% for placebo. Moreover, key secondary goals were also met, with the respective rates of ACR50 and DAS28 (CRP) ≤3.2 at week 24 for the zemprocitinib arm reaching 55.8% and 67.0%, respectively, compared with 22.0% and 23.4% for placebo.The company noted the experimental drug's safety profile was favourable, with most treatment-emergent adverse events being mild-to-moderate and no new safety signals were identified.Lyra suspends all drug development work Lyra Therapeutics will suspend further development of LYR-210 — a bioabsorbable implant designed to deliver six months of continuous mometasone furoate — for the treatment of chronic rhinosinusitis (CRS) in order to weigh strategic alternatives. The company cut 75% of its staff in mid-2024 following a Phase III failure for LYR-210.On Monday, Lyra said it will undertake another round of job reductions, which will impact its remaining 28 employees, as well as other cost-saving actions in order to buy more time. "The board has concluded that it is in the best interests of shareholders to cease Lyra's product development operations," remarked CEO Maria Palasis. The decision comes despite a second Phase III study of LYR-210 reading out positively this past June for the treatment of CRS without nasal polyps. Further, the company recently said that following a meeting with the FDA, it established a clinical development plan, which includes an additional late-stage trial to support the submission of a new drug application for LYR-210 in CRS without nasal polyps.As of September 30 last year, Lyra had approximately $22.1 million in cash, which is expected to last into the third quarter of 2026.BMS's Camzyos hits Phase III mark in teensBristol Myers Squibb reported positive topline results from a Phase III trial evaluating Camzyos (mavacamten) in 44 adolescents aged 12–17 with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The SCOUT-HCM study met its primary endpoint, showing a statistically significant reduction from baseline in Valsalva left ventricular outflow tract (LVOT) gradient at week 28 versus placebo, and achieved significance across multiple secondary endpoints as well. Safety findings were consistent with Camzyos' established adult profile, with no new safety signals.Camzyos, first approved by the FDA in 2022 for adults with symptomatic oHCM, has been prescribed to over 20,000 patients in the US alone. Monday's readout raises the possibility that Camzyos could become the first cardiac myosin inhibitor approved for adolescents, a population currently limited to medical symptom management or invasive surgery.BMS plans to present full results at an upcoming medical congress and engage with health authorities on potential regulatory submissions for adolescents.Last month, Cytokinetics' Myqorzo (aficamten) received FDA approval for adults with symptomatic oHCM.Matthew Dennis and Anna Bratulic contributed to this report.

Phase 3Phase 2Drug ApprovalClinical ResultLicense out/in

19 Dec 2025

·www.biospace.com

Insmed Delivers ‘Rare Disappointment’ as Brinsupri Flops in Mid-Stage Rhinosinusitis Study

iStock/ ALLVISIONN Insmed pointed to a strong placebo response as the reason for the trial’s failure. Insmed’s oral drug Brinsupri did not ease the burden of sinus symptoms in a mid-stage study of chronic rhinosinusitis without nasal polyps, forcing the New Jersey biotech to discontinue its program in this indication. Writing to investors on Thursday, analysts at Guggenheim Partners called the mid-stage miss a “rare disappointment” for Insmed—but one that nevertheless sent its shares tumbling 16% to $166.55 apiece at market close. “Based on our conversation with management, the BiRCh trial was well-conducted and delivered clear results, but the patients on placebo performed much better than expected,” Guggenheim noted. In the Phase IIb BiRCh study, Insmed enrolled nearly 290 patients who were randomly assigned to receive 10-mg Brinsupri, 40-mg Brinsupri or placebo, on top of their usual daily mometasone furoate nasal spray background therapy. Data presented on Thursday showed that at 24 weeks, patients given the respective doses of Brinsupri saw a 2.2- and 2.33-point decrease in the Sinus Total Symptom Score (sTSS), a tool used to measure rhinitis symptoms. While these changes indicated improvements due to treatment, there was also improvement in patients in the placebo arm, whose sTSS scores dropped 2.44 points at the same time point. In conversation with Guggenheim, Insmed management indicated that the BiRCh readout came earlier than expected. “Results were so unequivocal that they needed minimal time to process the results and decide to discontinue all further work in this indication,” the analysts said. Still, Guggenheim projects that the effects of Thursday’s rhinosinusitis fail will be “limited,” particularly given Brinsupri’s bright market prospects in non-cystic fibrosis bronchiectasis (NCFB). “We continue to see Brinsupri having ~$9Bn in peak sales potential in NCFB alone,” the analysts wrote. The BiRCh readout comes months after Insmed in June announced that its trepostinil palmitil inhalation powder (TPIP) aced a Phase IIb study in pulmonary arterial hypertension. Data presented at the time showed that TPIP led to a 35% improvement in pulmonary vascular resistance, a key measure of heart function, and to better six-minute walk distance. In its third quarter report , Insmed said that it would start a Phase III trial for TPIP in pulmonary arterial hypertension early next year. The biotech is also testing TPIP for pulmonary hypertension associated with interstitial lung disease, for which it expects to launch a late-stage study before the year ends. On Thursday, Guggenheim pointed to TPIP as one of the main reasons for its optimism about Insmed’s business. “We believe the Street continues to significantly underappreciate the potential for TPIP to become the preferred treprostinil across multiple large indications,” the analysts wrote.

Phase 2Clinical ResultPhase 3

18 Dec 2025

·www.fiercepharma.com

High-flying Insmed stumbles with rhinosinusitis trial failure for Brinsupri

With the failure of a phase 2 trial of Brinsupri in chronic rhinosinusitis without nasal polyps (CRSsNP), Insmed has discontinued its program to develop the newly approved, first-in-class DPPI inhibitor in the indication. Insmed has come up short in its attempt to expand its newly approved potential blockbuster Brinsupri into a new indication.With the failure of a phase 2 trial of Brinsupri in chronic rhinosinusitis without nasal polyps (CRSsNP), the New Jersey company has discontinued its program to develop the first-in-class DPPI inhibitor for the disorder, which would have brought a large patient population.The study did not meet any of its primary or secondary endpoints in either of the 10 mg or 40 mg treatment arms.As for the primary endpoint, Mizuho analyst Graig Suvannavejh, Ph.D., wrote in a note to investors that Brinsupri “failed spectacularly,” citing that patients had better outcomes with placebo than with either of the treatment doses.“Given that there are no animal models in this disease, the purpose of this proof-of-concept study was to determine if brensocatib could provide treatment benefit to patients with CRSsNP,” Martina Flammer, M.D., Chief Medical Officer of Insmed, said in a release. “While we are disappointed in the results, they provided us with a clear answer.”As a result, Mizuho sliced its peak annual sales projection for Brinsupri across all potential indications from $16 billion to $11 billion.After Insmed reported the failure late Wednesday, the company’s share price had fallen by 16% by mid-morning on Thursday.The lone positive from the trial is that Brinsupri was well-tolerated, with no new safety signals, including in the 40 mg arm, which is the highest dose the company has studied, exceeding its approved 10 mg and 25 mg dosages. In August, the FDA signed off on Brinsupri as a treatment for the rare respiratory disorder non-cystic fibrosis bronchiectasis (NCFB). In November, the European Union followed suit with a similar nod.In the same Dec. 18 release, Insmed announced the acquisition of Opsidio’s OpSCF, an investigational monoclonal antibody now known as INS1148. The company did not disclose financial details about the deal.Private Pennsylvania biotech Opsidio has been developing the antibody as a treatment for chronic inflammation. The program targets stem cell factor and was being developed in partnership with AbbVie.Opsidio was conducting a phase 2a trial of the asset in patients suffering from moderate-to-severe atopic dermatitis. Insmed is now picking up the program, which it believes has first-in-class potential for respiratory, immunological and inflammatory diseases with high unmet need, according to the release.Insmed said it plans on running phase 2 studies for INS1148 initially in interstitial lung disease and moderate-to-severe asthma. In the CRSsNP trial, which enrolled 288 participants across 104 sites, patients were randomized 1:1:1 for placebo, 10 mg Brinsupri and 40 mg Brinsupri. They received treatment for 24 weeks, which included the nasal spray background therapy mometasone furoate.As for the primary endpoint, the study used the patient-reported Total Nasal Symptom Score (TNSS), a 12-point measurement of a variety of nasal issues such as sneezing, runny nose, congestion and sleep disruption. While those on placebo reported a 2.44-point reduction from baseline, those in the 10 mg group reported a 2.21-point reduction and those in the 40 mg arm saw a 2.33-point reduction.Insmed is also investigating Brinsupri in the inflammatory skin disorder hidradenitis suppurativa (HS), with results from a phase 2 trial expected in the first half of next year. The company maintains an “optimistic view” in the indication because HS is a “strongly neutrophilic disease,” Muzuho reported, based on discussions with management on Wednesday night. Insmed has another lung disease drug on the market, Arikayce, which treats patients with mycobacterium avium complex (MAC). The amikacin liposome inhalation suspension treatment was approved in 2018 and generated sales of $364 million last year. In the first half of next year, Insmed expects to read out results from a trial of Arikayce as a first-line treatment for the disorder. The company also boasts a promising treatment for pulmonary arterial hypertension (PAH). In June, after reporting eye-opening phase 2 results for treprostinil palmitil inhalation powder (TPIP), Insmed saw a 27% spurt in its share price.

Phase 2Clinical ResultDrug ApprovalAcquisitionPhase 3

100 Deals associated with Mometasone Furoate

External Link

KEGG	Wiki	ATC	Drug Bank
D00690	Mometasone Furoate	R01AD09 R03BA07 D07XC03	DB14512

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Chronic rhinosinusitis with nasal polyps	United States	Intersect ENT, Inc.	08 Dec 2017
Asthma	United States	Organon & Co.	30 Mar 2005
Nasal Polyps	United States	Organon & Co.	15 Dec 2004
Pruritis (itchy skin)	Brazil	Libbs Farmacêutica Ltda.	28 Aug 2003
Rhinitis, Allergic	China	Schering-Plough Corp.	14 Jul 2000
Dermatitis	China	Merck & Co., Inc.	01 Jan 1999
Rhinitis, Allergic, Perennial	United States	Organon & Co.	01 Oct 1997
Rhinitis, Allergic, Seasonal	United States	Organon & Co.	01 Oct 1997
Alopecia Areata	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Drug Eruptions	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Eczema	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Erythema exudativum	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Erythrodermic psoriasis	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Impetigo	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Keloid	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Lupus Erythematosus, Discoid	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Pemphigoid, Bullous	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Pityriasis	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Prurigo	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Psoriasis	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic sinusitis	Phase 3	United States	Lyra Therapeutics, Inc.	27 Jan 2022
Chronic sinusitis	Phase 3	Austria	Lyra Therapeutics, Inc.	27 Jan 2022
Chronic sinusitis	Phase 3	Czechia	Lyra Therapeutics, Inc.	27 Jan 2022
Chronic sinusitis	Phase 3	Poland	Lyra Therapeutics, Inc.	27 Jan 2022
Chronic sinusitis	Phase 3	Spain	Lyra Therapeutics, Inc.	27 Jan 2022
Rhinitis perennial	Phase 3	China	Sichuan Otsuka Pharmaceutical Co. Ltd.	10 Apr 2019
Seasonal rhinitis	Phase 3	China	Sichuan Otsuka Pharmaceutical Co. Ltd.	10 Apr 2019
Sneezing	Phase 3	Argentina	PH & T SpA	01 Oct 2012
Congestion of nasal mucosa	Phase 3	-	Organon & Co.	01 Jul 2008
Intermittent asthma	Phase 3	-	Organon & Co.	01 May 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04849390 (ACESO, UEGW2024)	Phase 2	Eosinophilic Esophagitis	59	ESO-101 800 µg	bsgmowiihp(fuhhhppsyp) = tejmrxhrhw mbeidutwlp (liwfnxxoor, 88.42) View more	Positive	13 Oct 2024
				Placebo	bsgmowiihp(fuhhhppsyp) = gkztccbpdg mbeidutwlp (liwfnxxoor, 65.11) View more
NCT03979209 (CTgov)	Phase 1	Chronic sinusitis	16	Nasal Mometasone Rinse (Mometasone 1mg)	ugvmegytks(grmpfsewtm) = yykbuskozu feajlgljjp (mejgcqecyh, mvsluorevi - qqlqhjsmxx) View more	-	12 Aug 2024
				Nasal Mometasone Rinse (Mometasone 2mg)	ugvmegytks(grmpfsewtm) = fkwifvgshh feajlgljjp (mejgcqecyh, nntnjssnrj - zdplzozbog) View more
NCT04849390 ( ACESO , Biospace) Manual	Phase 2	Eosinophilic Esophagitis	43	ESO-101	glpzuwvguc(ojkaspnted) = met with a statistically significant reduction of the peak eosinophil count (p=0.0318) compared to placebo. qdbetyyzpw (dkkzrwesye )	Positive	05 Dec 2023
				placebo
NCT04041609 (CTgov)	Phase 2	Chronic sinusitis	71	LYR-210 (LYR-210 (Low Dose))	fqaqrcwvlm(yffbkyeljl) = qyrpzfvkdk cyctmzoctm (hegktddyyg, 0.637) View more	-	06 Jun 2023
				LYR-210 (LYR-210 (High Dose))	fqaqrcwvlm(yffbkyeljl) = xcdauhguav cyctmzoctm (hegktddyyg, 0.651) View more
NCT03705793 (CTgov)	Phase 4	Rhinitis, Allergic \| Chronic sinusitis	53	Mometasone Furoate Nasal Irrigation (Mometasone Furoate Nasal Irrigation)	xrvkfpwabs(oebrdsrgzm) = hluptdzemv qlkimunojf (ioyzbiopxx, shxjnfcmqs - ovbaqlhphj) View more	-	19 Dec 2020
				Mometasone Nasal Spray (Mometasone Nasal Spray)	xrvkfpwabs(oebrdsrgzm) = onxzgykdhy qlkimunojf (ioyzbiopxx, lfnlohmjeu - kkytltqhof) View more
NCT01850823 (CTgov)	Phase 3	Rhinitis, Allergic, Seasonal	880	Mometasone Nasal Spray (NASONEX® Nasal Spray (Schering Corporation))	icroiaildi(gothtlysng) = bbdbdqxtdw sezvprugck (jxeoaluxfn, 2.186) View more	-	19 Aug 2020
				Mometasone nasal spray (Mometasone Nasal Spray (Watson Laboratories, Inc))	icroiaildi(gothtlysng) = gggsanywzm sezvprugck (jxeoaluxfn, 2.223) View more
Pubmed \| Pulm Pharmacol Ther	Not Applicable	Asthma	739	Mometasone furoate 80 μg (Breezhaler®)	diycmaldrd(qtsqziavpo) = iiqfxrslon izcewkywyb (kkzcgajdps, -34 to 89)	-	01 Jun 2020
NCT02892344 (QUARTZ, Pubmed \| Respir Med) Manual	Phase 3	Asthma	802	indacaterol acetate+mometasone furoate	wfhnxtgjoh(fmwjgmbziy): LSMD = 0.182, P-Value = <0.001 View more	Positive	01 Jan 2020
				mometasone furoate
NCT03358329 (CTgov)	Phase 3	Nasal Polyps \| Chronic sinusitis	50	S8 Sinus Implant	ypyypyfedb = wohemoghts fbhhrjnclk (veyjufcqkg, galhggvzci - fshuyvadaq) View more	-	27 Nov 2019
B2208, B2209 (ERS2019)	Phase 2	Asthma	-	IND/GLY/MF o.d. 150/50/160 μg	exuqdgtbcg(oprslbqgpp) = xjnfoxoadj wqgsswxalv (ulheslrvoc, 66 - 142) View more	-	28 Sep 2019
				IND/GLY/MF o.d. 150/50/80 μg	exuqdgtbcg(oprslbqgpp) = lidvqrixyc wqgsswxalv (ulheslrvoc, 48 - 125) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis